Technical features:
The machines were primed with 1.5% isoflurane or 2.5% sevoflurane. Fresh gas flow (FGF) was set at 10 L·min -1 during the early washout phase, and subsequently reduced to 3 L·min -1 during the late washout phase. A Miran ambient air analyzer measured the anesthetic concentration every minute during washout until a concentration of 5 ppm was achieved in the inspiratory limb of the circle circuit. We found that at a FGF of 10 L·min -1 , maximum washout times for isoflurane and sevoflurane in the Primus, 70 and 74 min, respectively, were approximately tenfold greater than for isoflurane in the Excel 210 (7.0 min). Increasing the FGF to 18 L·min -1 decreased the washout time for isoflurane in the Primus, only moderately, to 52 min. We observed a threefold increase in anesthetic concentration in the Primus during the late washout phase.
Conclusion:
We conclude that the Primus must be flushed for at least 70 min to decrease the anesthetic concentration to 5 ppm when using a FGF of 10 L·min -1
. We recommend maintaining a FGF of 10 L·min -1 for the duration of anesthesia in order to prevent the rebound increase in anesthetic concentration in the FGF. 
Objectif : La préparation des appareils à anesthésie pour les patients susceptibles d'hyperthermie maligne comprend la purge de l'appareil avec des gaz frais sans vapeur pour éliminer les anesthésiques résiduels. Nous avons comparé les profils d'élimination de l'isoflurane et du sévoflurane des appareils à anesthésie Dräger Primus et Ohmeda Excel 210 pour établir des lignes directrices concernant la préparation de l'appareil Dräger Primus.

Éléments techniques : Une purge des appareils a été faite avec de l'isoflurane à 1,5 % ou du sévoflurane à 2,5 %. Le débit de gaz frais (DGF)
,
M
ALIGNANT hyperthermia (MH), a potentially lethal inherited metabolic disorder, can be triggered by inhalational anesthetic agents. Guidelines for the preparation of anesthetic machines for use in patients who are MH-susceptible include flushing the machine with vapour-free fresh gas to washout residual inhalational anesthetic agents. A ten-minute flush at a fresh gas flow (FGF) of 10 L·min -1 is commonly used in clinical practice. 1 This guideline is based on data derived from older style anesthetic machines such as the Ohmeda Excel 210 (GE Healthcare, Helsinki, Finland). The internal circuitry of new generation anesthesia machines is relatively complex and contains plastic and rubber components that can absorb and subsequently release anesthetic vapour. 2, 3 For such anesthesia machines, effective flushing can require considerably longer than ten minutes. 4 In the present study, we evaluated the washout profiles for isoflurane and sevoflurane in the Primus anesthetic machine (Dräger, Lübeck, Germany) in order to establish guidelines for the preparation of this machine for MH-susceptible patients. For comparison, we also evaluated the washout of isoflurane in the Excel 210.
Methods
We divided our study into four parts. In Part 1, we compared the washout profiles for isoflurane in the Primus and the Excel 210 anesthetic machines. Four Primus and two Excel 210 anesthetic machines were each studied in triplicate. All machines were primed for two hours with 1.5% isoflurane in air at a FGF of 2 L·min -1 . This was achieved using a circle breathing circuit, a test lung, and controlled ventilation with a tidal volume of 500 mL and a respiratory rate of 15 breaths·min -1 (minute ventilation, 7.5 L·min -1 ). On completion of priming, the vaporizer was removed from the machine, and the carbon dioxide absorber, circle circuit, and test lung were replaced with components that had not been exposed to inhalational anesthetics. In the Excel 210, we replaced the ventilator bellows and ventilator tubing as well.
To determine the washout profile for isoflurane, the FGF was set initially at 10 L·min -1 and the concentration of isoflurane in the inspiratory limb of the circle circuit was measured every minute (early washout phase). When the concentration of isoflurane in the inspiratory limb reached 5 ppm, the FGF was reduced to 3 L·min -1 to simulate a clinically relevant flow during anesthesia (late washout phase). Thereafter, the concentration of isoflurane in the inspiratory limb was measured every minute for an additional hour or until the concentration reached 5 ppm again. During the washout phases, a Miran SapphIRe 205B series portable ambient air analyzer (Thermo Electron Corporation, Waltham, MA, USA) was used to measure the concentration of isoflurane. This device is able to measure a wide range of chemical substances including anesthetic vapours using infrared spectroscopy. It has an accuracy of 5% and a sensitivity of 0.1 ppm. We calibrated the analyzer outside the operating room prior to each experiment.
In Part 2 of the experiment, we evaluated the washout profile for sevoflurane in the Primus anesthetic machine. Four Primus machines were studied in triplicate. We primed the machines for two hours with 2.5% sevoflurane to simulate a clinically relevant concentration. All settings during priming were the same as in Part 1 of the experiment. At completion of priming, the vaporizer was removed, and the carbon dioxide absorber, circle circuit, and test lung were replaced with components that had not been exposed to inhalational anesthetics. The early and late washout phases were conducted as in Part 1, and the concentration of sevoflurane in the inspiratory limb of the circle circuit was recorded every minute.
In Part 3, we evaluated the effect of FGF on the washout of isoflurane. Four Primus machines were studied in triplicate. The machines were primed, and the components replaced after priming as in Part 1. Fresh gas flows of 18 L·min -1 and 10 L·min -1 were used during the early and late phases of the washout, respectively, and minute ventilation was kept constant at 7. Table I .
Data are reported as mean ± SD. The MannWhitney rank-sum test was used to compare washout times. This test, rather than its parametric equivalent, was used because of between-group differences in variances. A Bonferroni correction was applied for multiple comparisons. P < 0.05 was considered statistically significant.
Results
In Part 1, isoflurane concentration decreased exponentially during the early phase of the washout, reaching 5 ppm in a maximum of 70 min (63.6 ± 5.1 min) in the Primus (Figure 1 ). Isoflurane concentration decreased approximately tenfold faster in the Excel 210, reaching 5 ppm in a maximum of seven minutes (6.7 ± 0.5 min) (P < 0.0001). During the late phase of the washout, we observed a rebound increase in isoflurane concentration in the inspiratory limb of the circle circuit (Figure 2 ). In the Primus, isoflurane concentration increased approximately threefold to 15.6 ± 0.9 ppm during the late phase of the washout and decreased slowly thereafter, remaining above 5 ppm for the duration of the experiment. In the Excel 210, isoflurane concentration increased to 8.4 ± 0.4 ppm during the late phase of the washout, returning to 5 ppm within 20.0 ± 6.0 min.
In Part 2, the washout of sevoflurane during the early and late phases in the Primus was almost identical to that for isoflurane (Figures 1 and 2 ). During the early phase, sevoflurane concentration decreased exponentially, reaching 5 ppm in a maximum of 74 min (64.6 ± 4.3 min). As for isoflurane, an approximate threefold increase in sevoflurane concentration was observed during the late washout phase, reaching 15.3 ± 0.8 ppm and then decreasing, but remaining above 5 ppm for the remainder of the experiment.
In Part 3, increasing the FGF to 18 L·min -1 accelerated the washout of isoflurane in the Primus only moderately ( Figure 1 ) (P < 0.0001); the washout time was still eightfold greater than that in the Excel 210 (P < 0.0001). During the early phase of the washout, isoflurane concentration decreased exponentially, FIGURE 1 Early washout profiles for isoflurane (Iso) and sevoflurane (Sevo) in the Primus and Ohmeda Excel 210. At a fresh gas flow (FGF) of 10 L·min -1 (FGF 10), isoflurane and sevoflurane concentrations decreased exponentially, reaching 5 ppm in a maximum of 70 min and 74 min, respectively, compared with a tenfold faster washout in the Excel 210 (7 min) (P < 0.0001). At a FGF of 18 L·min -1 (FGF 18), the washout of isoflurane in the Primus was only marginally faster, reaching 5 ppm in a maximum of 52 min. Doubling the minute ventilation had no significant effect on the washout of isoflurane (FGF 10 -high minute ventilation). Data are mean ± SD. MV = minute ventilation. reaching 5 ppm in a maximum of 52 min (48.6 ± 2.7 min) in the Primus. During the late phase of the washout, isoflurane concentration increased to only 5.9 ± 0.1 ppm, returning to 5 ppm within 11 ± 1.7 min (Figure 2) .
In Part 4, doubling the minute ventilation had no effect on the washout time for isoflurane (Figure 1) . At a minute ventilation of 15 L·min -1 , isoflurane concentration decreased exponentially during the early washout phase, reaching 5 ppm in a maximum of 77 min (71.5 ± 5.4 min) in the Primus. The rebound increase in isoflurane concentration during the late washout phase was similar to that observed in Part 1 ( Figure 2 ). Washout times are summarized in Table II .
Discussion
The results show that washout times were approximately tenfold greater for the Primus than for the Excel 210 under the conditions of the current study. Maximum anesthetic washout time was 70 min or greater in the Primus and decreased only to 52 min when the FGF was increased to 18 L·min -1 . Even at a FGF of 18 L·min -1 , the washout time for isoflurane was approximately fivefold greater than the ten-minute flush recommended in some current guidelines. 1 In addition, we noted a threefold increase in anesthetic concentration in the Primus when the FGF was reduced to a clinically relevant rate during the late washout phase. A similar increase in anesthetic concentration has been reported previously for the Siemens Kion anesthesia machine 4 (Siemens Elema, Solona, Sweeden).
The greater washout time and the rebound increase in anesthetic concentration in the Primus may be attributed to several factors. First, the internal circuitry of the Primus is compartmentalized, 5 resulting in complex gas flow dynamics and the potential for residual pockets of fresh gas containing relatively high concentrations of anesthetic vapour that can be flushed out only slowly. Second, the internal circuitry consists in part of non-exchangeable plastic and rubber components. Inhalational anesthetics dissolve into and subsequently elute slowly from these components. 2, 3 Third, to prevent dependency of tidal volume on FGF, the Primus utilizes a principle referred to as fresh gas decoupling, 5 in which the ventilator and the inspiratory part of the internal circuitry are decoupled from the fresh gas unit in inspiration. Thus, fresh gas passes to the manual ventilation bag via the carbon dioxide absorber in inspiration, and is subsequently fed directly into the breathing system together with the stored volume via a non-return valve (fresh gas decoupling valve) in expiration. Accordingly, the inspiratory part of the internal circuitry is flushed only intermittently during the respiratory cycle. The relative importance of these factors remains to be established. Previous studies evaluating the washout profiles of inhalational anesthetics in other anesthesia machines have used various priming concentrations, measurement techniques, FGFs, and concentration endpoints. 4, [6] [7] [8] [9] We used a priming concentration of 1.5% for isoflurane and 2.5% for sevoflurane in order to evaluate these volatile agents at clinically relevant concentrations. We measured anesthetic concentrations using a Miran SapphIRe 205B series portable ambient air analyzer, which uses infrared spectroscopy and has a sensitivity of 0.1 ppm. This method of analysis has the advantage over other previously used methods such as gas chromatography of being able to measure anesthetic concentration within the breathing circuit contemporaneously. During the early washout phase of the experiment, we studied the effect of two different FGF rates on the washout of anesthetic vapour. The first, 10 L·min , is commonly used in clinical practice. 1 The second, 18 L·min -1 , is the maximum FGF that can be delivered by the Primus machine. In addition, because the fresh gas decoupling mechanism limits flushing of the internal inspiratory circuit to specific times in the respiratory cycle, we studied the effect of minute ventilation on washout. Our results suggest that increasing neither FGF nor minute ventilation has a clinically relevant effect on the washout of inhalational anesthetics from the Primus.
During the early washout phase of the experiment, we flushed the anesthetic machines until the concentration in the breathing circuit reached 5 ppm. Previous authors have used endpoint concentrations ranging from 1 ppm to 10 ppm. 4, 6, 7, 9 The minimum concentration of inhalational anesthetic needed to trigger an MH reaction in humans is unknown and will probably remain unknown because it would be unethical to expose MH-susceptible patients to inhalational anesthetics; however, evidence suggests that MH-susceptible swine do not develop MH when exposed to 5 ppm of halothane.
A Additionally, ambient operating room anesthetic concentrations were frequently in the range of 1 to 5 ppm before gas scavenging became standard in the operating room, and to our knowledge there are no reports of MH reactions in health care workers exposed to the operating room environment. Considering those facts, we chose a vapour concentration of 5 ppm as a valid measurement endpoint. If an endpoint of 10 ppm is considered, the flush time for the Primus at a FGF of 10 L·min -1 is 34 min, compared with 25 min for the Siemens Kion. 4 In summary, to prepare the Primus anesthetic machine for use in MH-susceptible patients, the machine must be flushed for at least 70 min to achieve an anesthetic concentration of 5 ppm when using a FGF rate of 10 L·min -1
. We recommend maintaining a FGF of 10 L·min -1 throughout the duration of anesthesia in order to prevent an increase in anesthetic concentration in the FGF. Increasing the FGF or minute ventilation is of limited clinical value in accelerating anesthetic washout from the Primus anesthetic machine. In addition, we recommend that guidelines for the preparation of anesthetic machines for MHsusceptible patients should be specific for each type of machine. Alternatively, a dedicated vapour-free anesthesia machine may be used for MH-susceptible patients. Near infrared spectroscopy monitoring during pediatric aortic coarctation repair 
Summary
Background: Near infrared spectroscopy (NIRS) measures regional tissue oxygenation continuously and noninvasively and may allow assessment of changes in regional perfusion in real time.
Methods: We used NIRS monitoring to track real-time changes in regional oxygenation (rSO 2 ) above and below the aortic cross-clamp in patients undergoing aortic coarctation repair and routinely stored these data in an operative electronic data base. This allowed us to analyze the changes in rSO 2 during aortic coarctation repair for three pediatric age groups (neonates, infants <1 year, and children >1 year).Two site [cerebral (rSO 2 -C) and somatic thoracodorsal (rSO 2 -S)] rSO 2 monitoring was performed in patients undergoing aortic coarctation repair. Data for rSO 2 were analyzed across sites and age groups before, during and after cross-clamp. Results: Twenty-six patients were available for analysis (11 neonates, 5 infants and 10 children). The regional oxygenation below the cross clamp (rSO 2 -S) declined significantly in all three age groups, but the decrease in neonates and infants <1 year of age was significantly greater than in the older children. Conclusions: Monitoring rSO 2 -S provides real-time trend information of regional oxygenation below the aortic cross-clamp. The decline in rSO 2 -S during aortic cross-clamp was rapid and large in most neonates and young infants <1 year which suggests impairment of regional perfusion presumably because of a lack of adequate collateral circulation to the monitored regional tissue. In contrast, the rSO 2 -S changed only to a minor degree in most infants and children >1 year, possibly because they had time to develop a more adequate collateral circulation around incomplete aortic obstruction.
Introduction
Aortic coarctation repair may place tissues distal to the cross-clamp at ischemic risk. Spinal cord ischemia has led to paraplegia in children as young as 2 months of age (1) . Prolonged splanchnic ischemia preceding repair can also lead to renal failure, ischemic hepatitis and necrotizing enterocolitis (1-4). However, currently employed monitoring methods such as differential invasive blood pressure or somato-sensory evoked potentials of the spinal cord rarely identify endorgan ischemia (5) (6) (7) (8) . It is possible that in most patients the presence of an adequate collateral circulation protects the infraclamp organs against such injury. Near infrared spectroscopy (NIRS) of regional oxygen saturation (rSO 2 ) has only been clinically approved for cerebral monitoring. However, Hoffman et al. (9) have used two site rSO 2 monitoring during open heart surgery for congenital heart disease, utilizing frontal cerebral (rSO 2 -C) and dorsolateral T10-L2 renal/somatic probe sites (rSO 2 -S) to reflect changes in regional oxygenation in circulations under different physiologic control. Monitoring rSO 2 provided real-time information about changes in regional tissue oxygenation during total circulatory arrest, venous cannula obstruction or sudden global hypoxemia. It also showed that somatic saturation progressively decreased during isolated cerebral perfusion (9) . We have extended routine rSO 2 monitoring to other clinical situations where regional circulations may be at risk, such as during cross-clamping of the proximal descending aorta in children undergoing aortic coarctation repair.
We expected that aortic cross-clamping would lead to prompt and progressive decreases in rSO 2 -S below the clamp, if collateral circulation is inadequate. We hypothesized that neonates and infants would demonstrate more profound decreases in rSO 2 -S below the clamp as they are less likely to have developed an adequate collateral circulation other than a persistent ductus arteriosus. However, children presenting for repair beyond 1 year of age would be more likely to have developed adequate collateral circulation around incomplete aortic obstruction. The purpose of this pilot study is to describe the changes in rSO 2 during aortic cross clamping for aortic coarctation repair in three pediatric age groups.
Methods
We obtained institutional review board approval to review all available rSO 2 data that were prospectively collected on all cardiovascular surgery patients as well as the perioperative clinical records of patients undergoing isolated aortic coarctation repair via left thoracotomy under general anesthesia between September 2002 and April 2004. We routinely monitor two site rSO 2 data in this population and maintain an electronic data base for quality assurance. The rSO 2 -C sensor was placed across the middle of the forehead from right to left side. The rSO 2 -S sensor was placed on the back, with the free end oriented toward the spine and the connector end to the flank, in the thoracodorsal (T-10 -L2) region. Data (Pediatric SomaSensor, Model SPFB, for children 4-40 kg by Somanetics Corporation, Troy, Michigan for the INVOS 5100 Cerebral Oximeter) were continuously updated at two readings per second and average recordings saved at 1-min intervals.
We identified 26 infants and children with complete two site rSO 2 data. Anesthetic technique and the extubation status at the end of the operation was recorded for all patients. As we hypothesized that the status of collateral circulation during crossclamp will show age dependent differences, patients were grouped patients as neonates (age 6 30 days), young infants (age: >30 and 6365 days) or children (age > 365 days). All rSO 2 data were analyzed across these three age groups for the two sites. Average values of 10 min periods before crossclamp (baseline), during cross-clamp and recovery after cross-clamp were analyzed for differences between rSO 2 -C, rSO 2 -S and across age groups. Student's t-test for rSO 2 comparisons before and after cross-clamp within an age group or a one-way analysis of variance with Bonferroni's correction for multiple comparisons between age groups was performed.
Results
Twenty-six patients were available for analysis (11 neonates, 5 infants and 10 children). All patients received a volatile anesthetic supplemented with low doses of opioids. In addition five of 10 neonates, three of five infants and three of 10 children >1 year received a single dose of caudal epidural morphine (100 lgAEkg )1 ). At then end of the operation six of 10 neonates, three of five infants and nine of 10 children >1 year were extubated in the operating room. Table 1 summarizes the median age and range, gender distribution and aortic cross-clamp times for the three age groups. Figure 1 shows the mean rSO 2 values for the 10-min intervals prior to, during and after cross-clamp of the aorta for the three age groups for the cerebral region, rSO 2 -C. Infants had lower baseline rSO 2 -C values than neonates or children during the precross-clamp period and during the recovery period. For all age groups rSO 2 -C values trended up during aortic cross-clamp. Figure 2 shows the rSO 2 -S data for the region below the cross-clamp. It shows a large progressive drop in the rSO 2 -S for the neonatal and the infant groups, but only a small change for the children >1 year during aortic cross-clamping, with prompt recovery after release of the cross-clamp in all three age groups. Table 2 shows the average rSO 2 values for each 10-min interval. The average rSO 2 -C increased slightly in all three age groups during cross-clamp but this was only significant for the children >1 year (P < 0.05). The average rSO 2 -S during cross-clamp was significantly lower than baseline for all three age groups (P < 0.001 for neonates and infants, P < 0.01 for children >1 year). The average rSO 2 -S values for the children >1 year of age remained significantly higher (P < 0.01) during cross-clamp than in the neonatal and infant groups. The absolute decline in average rSO 2 -S during cross-clamp was also significantly greater in the neonates and infants (P < 0.001).
Discussion
Our regional oxygenation data show that most neonates and infants <1 year have a large and progressive decrease in regional oxygenation below the cross-clamp while older children (>1 year) showed no or much smaller decreases. The pronounced and usually progressive decrease in Changes in somatic regional oxygenation (rSO 2 -S) for the three age groups immediately before, during and after aortic cross-clamp. Each data point is the group mean ± confidence interval for that minute. XC ¼ aortic cross-clamp. See text for details.
regional oxygenation below the cross-clamp (rSO 2 ) in neonates and infants <1 year of age suggests that these patients may be at greater risk of ischemichypoxic injury compared with older patients. The rapidity of the drop in rSO 2 -S during the first few minutes of cross-clamp and the progressive decline, which we observed in most neonates and infants is comparable with changes seen at the same site during body circulatory arrest with selective cerebral perfusion (9) . We speculate that this marked drop in the younger patients reflects inadequate collateral circulation other than a shunt via a patent ductus arteriosus which would be eliminated during cross-clamping. It is noteworthy that one patient >1 year of age had an rSO 2 -S profile similar to the neonates and this patient's collateral circulation may have been quite compromised because both the left subclavian artery and an aberrant right subclavian artery were included in the cross-clamp. The subclavian arteries give rise to the vertebral arteries, which provide blood flow to the anterior spinal artery, which is the major source of upper spinal cord blood flow. As more neonates had a ductal dependent circulation than infants and none of the children >1 year, the lower baseline rSO 2 -S values are likely related to ductal shunting of lesser oxygenated blood to the lower body before cross-clamping. We have no obvious explanation for the lower baseline rSO 2 -C values in the infants, since a review of baseline pulse oximetry data did not show a significant difference in arterial saturation between the groups. Differences in P a CO 2 can significantly alter cerebral regional oxygenation values while having little impact on somatic regional oxygenation. However, we also did not observe any significant differences in endtidal CO 2 between the groups. All patients were monitored with pediatric rSO 2 probes and the difference in the size of the patients may lead to different optical pathway lengths but we have no explanation how this factor would lead to lower baseline rSO 2 -C saturations specifically in the infants. Thus the small number of infants that were studied may partially explain the greater variability in this group.
Although the rSO 2 data collection were prospective and complete and anesthetic management relatively uniform, we acknowledge that our data are merely descriptive and that the study has several limitations. First, we did not have an independent method to reliably assess the status of the collateral circulation and clinical data for such an assessment were too incomplete to make valid comparisons with the rSO 2 data. Secondly, the somatic rSO 2 data reflect impairment of regional oxygenation underneath the thoracodorsal probe site. It is possible that the vertebral arterial system, which provides flow to the anterior spinal artery was not impaired in most of our patients and that the vertebral arteries provided adequate perfusion via the anterior spinal artery for the whole spinal cord during crossclamping, i.e. our thoracodorsal rSO 2 measurements probably do not adequately reflect changes in spinal cord perfusion. Thirdly, because clinically apparent ischemic-hypoxic injury after coarctation repair is rare, our case series is far too small to detect differences in clinical outcome. Such outcome studies require recruitment of thousands of patients to detect differences in rare events.
There is good evidence that monitoring rSO 2 provides a real-time continuous assessment of regional oxygenation of a variety of tissue beds. In conclusion, we found that rSO 2 -S monitoring provides real-time trend information of regional oxygenation below the aortic cross-clamp. The decline in rSO 2 -S during aortic cross-clamp was rapid and large in most neonates and young infants <1 year, which suggests impairment of regional perfusion presumably because of a lack of adequate collateral circulation to the monitored regional tissue. In contrast, the rSO 2 -S changed only to a minor degree in most infants and children >1 year, possibly because they had time to develop a more adequate collateral circulation around incomplete aortic obstruction.
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None. IV drug infusion has the potential for dosing errors, which arise from complex interactions between carrier flows and the infusion set dead volume. We computed the steady-state mass of drug stored in the infusion set dead volume, using phenylephrine as a model compound. The mass of drug in the dead volume increases with stock drug concentration and desired dose but decreases with carrier flow rate. We also modeled the dynamic perturbations in drug delivery when a carrier is abruptly stopped. Rapid initial carrier flow rates lead to greater depression in drug delivery rate after carrier flow ceases. Rapid drug infusion rates lead to faster restoration of desired drug delivery. Finally, the time to reach a new steady-state after a change in drug delivery or carrier rate was computed. This time is longest for large stock-drug concentrations, larger dead volumes, and slower final carrier rates. These computations illustrate that (a) the dead volume may contain a large mass of drug available for inadvertent bolus, (b) cessation of carrier flow can profoundly reduce drug delivery, and (c) after a change in carrier flow or drug dosing, a significant lag is possible before drug delivery achieves steady state. Although computed for phenylephrine, the concepts are generic and valid for any drug administered by IV infusion.
The Delivery of Drugs to Patients by Continuous Intravenous Infusion: Modeling Predicts Potential Dose Fluctuations Depending on Flow Rates and Infusion System Dead Volume
( Vasoactive, antidysrhythmic, inotropic, and sedative and analgesic drugs are often infused into surgical patients under anesthesia in the OR or critically ill patients in the intensive care unit (ICU). Precise control of the delivery of powerful cardio-stimulatory drugs such as epinephrine, vasopressors such as phenylephrine, or vasodilators such as nitroglycerin or sodium nitroprusside is essential to achieve desired therapeutic end-points and to avoid deleterious fluctuations in the patient's clinical condition. The basic components of an infusion system include (a) a reservoir of the drug to be infused, (b) a device to control the rate of drug egress from the reservoir, and (c) a tubing system connecting the rate control device to the fourth component, which is the vascular access catheter. A fifth component, a mainline or carrier flow, may also appear in some clinically used infusion systems (1, 2) . In this case, the drug infusion joins the mainline or carrier flow at a junction point upstream from the patient.
Frequently, pumps are used to drive the delivery of IV infused drugs in a controlled fashion. Previous studies have examined pump performance characteristics (3) (4) (5) (6) (7) (8) (9) (10) (11) . Experimental data demonstrated that cyclic changes in pump output, determined by the mechanical features of the pumps, correlate with hemodynamic fluctuations (3, 5, 6, 8) . Consequently, considerable attention has been directed towards optimizing pump design to reduce the likelihood of clinically significant fluctuations in drug delivery (1, 2) .
Less attention has been paid to other components of the infusion system. Whereas drugs may be infused directly into the patient, limited vascular access or the need to simultaneously provide two or more IV fluids means that drug infusions may join a mainline carrier infusion. Many patients are intolerant of fluid loads (12, 13) . Thus, at some institutions the amount of fluid infused into patients has been reduced by increasing the stock concentration of drugs (14) . Consequently, the desired mass (dose) of drug is delivered in a small volume. Whereas the patient potentially benefits from a reduced volume load from concentrated stock drug, clinical experience suggests the possibility of an enhanced risk for unplanned changes in drug delivery (14) . This risk can be attributed to unrecognized reservoirs of concentrated drug within the IV infusion set. These changes may have significant clinical consequences, such as profound vasoconstriction, vasodilation, or loss of inotropic support. Indeed, in the clinical vignette described above, a real case managed by experienced clinicians, we suspect that the phenylephrine infusion driven by the syringe pump accumulated in the IV tubing when the main IV flow stopped during the transport interval. When the IV bag was resuspended on a pole in the PACU, the patient received a large bolus of vasopressor resulting in the episode of hypertension.
We have previously described and experimentally validated theoretical models to characterize the dynamics of drug delivery by IV infusion (15) . Factors anticipated to affect drug delivery include the flow rate of the mainline or carrier infusion (Q c ), the flow rate of the drug infusion (Q d ), and the infusion system dead volume (V) defined as the volume between the point where the stock-drug infusion joins the carrier and the patient's blood stream. The models were tested empirically, and the predictions of the models approximated the experimental findings. In the present study, we calculate the mass of drug stored in the reservoir of the dead volume and use the previous models to predict changes in drug delivery depending on alterations in carrier flow and infused drug dose rate. The findings extend the previous work by illustrating in greater detail the possibilities for interplay among Q c , Q d , and V, and the magnitude of perturbations in drug delivery when these factors are altered.
Methods
All of the following equations are generic, applicable to any infused drug, and assume an infusion system architecture in which a flow of drug ('piggyback') joins a carrier. A joining point might be at the side port of an IV extension set or a stopcock. At steady-state, the concentration of the drug throughout the dead volume (C v ) is given by the dilution of the stock-drug concentration (C d ) by the carrier flow rate (Equation 1).
Q d is the drug infusion rate (I), in units of mass per unit time, divided by C d . Substituting this relationship into Equation 1 shows:
The total mass of drug in the dead volume (M V ) is a function of the dead volume and the concentration of drug in the fluid path.
This would be the mass of drug available for a bolus, should the carrier rate abruptly increase, or if there is an upstream 'push' of fluid (e.g., another drug). The potential drug bolus residing within the reservoir of the infusion system dead volume was calculated as a function of drug infusion dose (I), with varying Q c , C d , and V.
In clinical practice, carrier flows sometimes stop inadvertently, as when a bag of crystalloid empties unnoticed. In this scenario, the rate of drug delivery into the patient initially decreases as the reservoir of diluted drug in the dead volume now infuses at a much slower rate, given by:
Initial Delivery rate after carrier ceases ϭ
The return of drug delivery to the planned steadystate while the carrier infusion is off was previously described by two models of crystalloid and drug flow within V (15). These models make divergent assumptions about the mixing of drug infusion and carrier flows. The plug-flow model assumes that the streams of drug and carrier mix perfectly at the point where they meet. The mixed fluid in this model is assumed to travel downstream as a plug. Changes in the rate of drug infusion propagate along the fluid path according to the total flow rate, the sum of the carrier and drug flow rates. After a change in either the carrier flow or the drug infusion flow rate, the time to achieve the planned steady-state delivery of drug is one time constant ():
At the other extreme, the well-mixed model assumes that the concentration of drug everywhere in the dead volume is uniform (15) . After a change in either the drug infusion or carrier flow rate, the time to achieve the planned steady-state delivery of drug is approximately three time constants, threefold more than in the plug-flow model (15) . The equation describing drug delivery to the patient after the carrier is halted appears in the Appendix.
We used these equations to predict the potential bolus of drug stored in the reservoir of the deadvolume (M V ; Fig. 1 ). We then explored the consequences of abruptly turning off a carrier by calculating the drug delivery rate just after carrier flow ceases (Fig. 2) and the time course for reestablishing steadystate as predicted by the well-mixed and plug-flow models (Figs. 3 and 4) . Finally, we generalize the interaction between the carrier flow and the dead volume by calculating the time to achieve steady-state after a change in either flow rate (Fig. 5) . Computations covered a range of drug infusion doses, carrier flows, stock-drug concentrations, and dead volumes. Major assumptions in these calculations are that the pump driving the drug infusion operates without fluctuations and that any carrier flow is continuous without any fluctuations in rate unless specified.
Phenylephrine is frequently used in the OR or the ICU and is chosen as a representative infused vasoactive drug. The principals should apply, however, to any drug delivered by continuous IV infusion, including vasopressors such as epinephrine or norepinephrine, vasodilators such as nitroglycerine or sodium nitroprusside, analgesics such as remifentanil or fentanyl, or sedative-hypnotic drugs including propofol.
Results
The concentration of a drug in the dead volume of an infusion system at steady-state depends on the flow rate of the carrier fluid diluting the infused drug. For a given planned drug infusion rate, the dead volume drug concentration decreases as the carrier rate increases (Equation 2). At slow carrier rates (I/C d Ͼ Q c ), the stock concentration of drug is only slightly diluted. At steady-state there is a predictable mass of drug in the dead volume (Fig. 1A) . For example, at a planned phenylephrine infusion dose of 100 g/min, a dead volume of 2 mL, a stock concentration of 1.2 mg/mL, and a carrier rate of 10 mL/h, there are 800 g of phenylephrine contained in the dead volume reservoir at steady-state. Alternatively, if the carrier flow rate was 100 or 500 mL/h, the drug stored in the dead volume would be 114 or 24 g, respectively. Conversely, if the infusion ran without a carrier, as is the practice in some ICUs, the dead volume would store 2.4 mg of phenylephrine regardless of the infusion rate (Q c ϭ 0). These drug masses would be potentially available as boluses should the carrier flow rate abruptly and dramatically increase or if a flush of crystalloid or other drug is given upstream through the infusion tubing. In general, the mass of drug stored in the dead volume increases with drug infusion dose rate, the stock concentration of drug (Fig.  1B) , and the size of the dead volume (Fig. 1C) .
The impact of an alternative possibility, the abrupt cessation of a carrier flow, on drug delivery was also investigated. The total flow of fluid reaching the patient's vasculature is the sum of the carrier and infused drug flows. As carrier flow abruptly ceases, fluid enters the patient only at the rate of the flow of infused drug. However, the concentration of drug will initially be small, reflecting the earlier dilution of drug by the carrier fluid. Consequently, the patient will initially receive a reduced drug dose for some time.
For example, as predicted for phenylephrine (C d ϭ 1.2 mg/mL; I ϭ 100 g/min; Q c ϭ 10 mL/h) the steadystate concentration of drug at the most downstream end of the infusion set will be 0.4 mg/mL. When the carrier abruptly ceases the total flow rate decreases from 15 to 5 mL/h, resulting in an initial drug infusion rate of 33 g/min (Fig. 2) . The slower the carrier flow before cessation, the closer the initial resulting infusion remains to the desired dose. At rapid planned drug infusion rates, the impact of suddenly stopping the carrier is diminished. In both of these instances, the drug infusion rate (Q d ) is rapid relative to the carrier rate (Q c ), and therefore, the initial dilution from the carrier is minimized. However, with rapid carrier flow before cessation, there is an initial large reduction in drug delivery. Note that these effects are independent of the dead volume (Equation 4) but depend on the relative rates of drug and initial carrier flow.
In the event that the carrier flow is not restored and drug infusion continues, both the plug-flow and the well-mixed models predict that the planned dose of drug will eventually be delivered, albeit with different kinetics (Fig. 3) . The plug-flow model predicts an abrupt restoration to steady-state in one time constant, whereas the well-mixed model predicts a gradual return in approximately three time constants. The delay until the planned delivery is restored depends on the rate of drug infusion, the stock-drug concentration, and the size of the dead volume (Equation 5 with Q c ϭ 0; Fig. 4 ). In the case of phenylephrine with a planned delivery of 150 g/min and a dead volume of 2 mL (C d ϭ 1.2 mg/mL), the plug-flow model predicts a delay of 16 min from cessation of the carrier until restoration of steady-state. Drug delivery remains under-dosed until the 'plug' of infused medication traverses the dead volume in one time constant. The Figure 2 . Drug delivery rate immediately after carrier flow cessation, as a function of planned phenylephrine dose for initial carrier flow rates of 0, 10, 100, and 500 mL/h (C d ϭ 1.2 mL/h). The drug delivery is temporarily reduced when a carrier stops. The drug delivery rate is less than planned because dilute drug in the dead volume suddenly flows at a slower rate. The more rapid the initial carrier flow, the larger this reduction in drug delivery. Figure 3 . An example of the drug delivery after cessation of the carrier at zero minutes as described by the plug-flow and wellmixed models (V ϭ 2 mL; C d ϭ 1.2 mg/mL; I ϭ 200 g/min). Drug delivery is initially reduced and returns to steady-state with kinetics that depend on the model. Whereas the plug-flow model shows a 50% reduction in delivered phenylephrine until the dead volume is completely turned over in one time constant, the well-mixed model predicts the same initial reduction, but a gradual return to steadystate over approximately three time constants. Both models have been previously described and experimentally validated (15) . Time to achieve steady-state after carrier cessation as a function of the dead volume, based on the plug-flow (lower bound, solid) and well-mixed (upper bound, dashed) models for planned phenylephrine doses of 40, 150, and 500 g/min (C d ϭ 1.2 mg/mL). Note that the plug-flow model predicts a return to steady-state in one time constant (lower bound, solid), and the well-mixed model predicts a return to steady-state in approximately three time constants (upper bound, dashed). The actual time to steady-state must lie between the boundaries predicted by the two models, within the shaded regions. An example of the kinetics by which drug delivery returns to steady-state is shown in Figure 3 . well-mixed model predicts a gradual return to steadystate in approximately three time constants or 48 min. Should the absence of carrier flow be recognized and then become abruptly restored, the dead volume will contain stock drug, which may enter the patient as an undesired and potentially delayed bolus (15) . The magnitude of the bolus will depend on the rate of infused drug flow, the size of the dead volume, the stock drug concentration, and the time elapsed without carrier flow.
The plug-flow model predicts the minimum time (one time constant) for achieving steady-state after changing either the drug infusion dose or the carrier rate (Equation 5; Fig. 5 ). This transition period is the time for a change in drug dilution by the carrier to propagate through the infusion system dead volume. The minimum delay will increase along with the size of the dead volume (Fig. 5A ) and with the concentration of the drug in the stock solution (Fig. 5B) . The delay decreases with carrier flow rate. The well-mixed model predicts a threefold longer time to achieve steady-state. The actual time to return to steady-state is between the boundaries defined by the plug-flow and well-mixed models (15) .
Discussion
The use of continuous medication infusions is common in the clinical environments of the OR and the ICU. This is because many medications used in these environments, such as epinephrine or nitroglycerin, have short half-lives in the circulation. Sustained therapeutic effects can only be achieved with continuous infusion. In settings where the clinical condition of a patient may fluctuate rapidly, as during surgery or even in an ICU environment, there is a significant advantage to using medications whose effects are readily titratable.
Under-or over-dosing of powerful medications can have significant consequences. A bolus dose of phenylephrine or norepinephrine, if untreated, would probably result in significant vasoconstriction and hypertension lasting for at least a few minutes. Whereas some patients may tolerate this fluctuation in hemodynamics, those with failing ventricles, aneurysms, or tenuous tissue blood flow would be at risk for catastrophic complications. Conversely, a bolus dose of nitroglycerin or nitroprusside would, if untreated, probably result in significant hypotension lasting for at least a few minutes. Some patients with certain clinical conditions, such as aortic stenosis or vasoocclusive disease of the cerebral or coronary circulations, might suffer sustained morbidity. The modeling demonstrated in this study, and validated in our previous study (15) , predicts that such boluses of vasodilators and vasoconstrictors can occur under clinical conditions.
The potential for unplanned bolus delivery may be unrecognized because the magnitude of dead-volume reservoirs is unappreciated. IV infusion systems and various intravascular catheters may have significant dead volumes, ranging up to several milliliters ( Table  1) . As a rule of thumb, the maximum drug mass stored in the dead volume equals the dead volume multiplied by the stock-drug concentration (Equation 3 with Q c set to zero). If, for example, an infusion of phenylephrine or any other drug is mainlined into the side port of a pulmonary artery catheter introducer sheath, with a dead-space volume of 2.75 mL, a potential drug reservoir of hundreds to thousands of micrograms is established. This may be a safe and effective practice in the circumstance where one caregiver, such as an anesthesiologist or ICU nurse, is the The real return to steady-state is in between these extremes. Any change to the carrier flow rate, infusion dose, or even stock concentration is associated with a predictable delay in achieving a new steady-state.
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sole provider. However, in situations where multiple caregivers are involved, or when there is hand over of a patient from one team to another (for example, OR anesthesia team to ICU team or vice versa), the potential for error and harm is significant. The predictions illustrated in this study concerning the time course of the return to steady-state after a perturbation in carrier or infusion dose rate are based on previously derived and validated computational models of IV delivery (15) . An essential variable of the plug-flow model is the time constant, , defined as the ratio of dead volume over total flow (Equation 5 ). This model fails to account for diffusion or dispersion of drugs within the infusion line, which may be significant at extremes of carrier flow. The well-mixed model better accounts for drug dispersion (15) , and after any perturbation, predicts a gradual return to steady-state over three time constants. In reality, drug infusions likely behave between the extremes defined by these two models. This would effect only the absolute magnitudes of under-or over-dosing and the absolute duration of delays in drug delivery.
All of the predictions have been illustrated with phenylephrine; however, the equations are generic and can be applied to any drug given by IV infusion. The results of this study assume a fixed carrier flow rate. In reality, carriers are often gravity-driven so that flow will vary according to the height of the carrier fluid reservoir above the patient's central venous pressure and with outflow resistance produced by a poorly running IV line. This adds a level of complexity to estimating the absolute concentrations of drugs in infusion tubing and the potential size of boluses. Also, with gravity-driven carriers, there may not be a true steady-state. With placement of a BP cuff proximal to the cannulation site, the flow rates become even more unpredictable.
To minimize safety problems, clinical personnel must first recognize the complexities of drug delivery by IV infusion. When transitions of care occur between providers, explicit descriptions of the architecture of infusion systems must be thoroughly communicated. However, practical steps to reduce the likelihood of drug errors would include (a) minimizing dead volume when constructing infusion setups, (b) ensuring a fixed rate of carrier flow, (c) using pumps with minimal fluctuations in output, and (d) mechanically preventing the possibility of upstream pushes of fluid, as by removing or blocking upstream side ports or stopcocks. Reducing the stock concentrations of infused drugs would build in safety, but this comes at the price of obligate additional fluid delivery to the patient.
Medication error accounts for a significant portion of preventable patient morbidity (16) . Our findings are consistent with a role for infusion errors in patient morbidity attributable to methods of medication administration. The concepts presented in this study, whereas perhaps intuitive, may not receive full appreciation by novice caregivers, when multiple caregivers are involved, or when the clinical situation becomes particularly dynamic, such as during a resuscitation event. The models allow quantitative estimates of the magnitudes of dose alterations and delays in drug delivery. Recognition may ultimately have a patient safety benefit. 
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